Drugs / IPN60340
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07623187 | Nov 2026 → May 2031 expected | acute myeloid leukemia | Ipsen | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-13 | Ipsen | Regulatory U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia ipsen.com ↗
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-13 | Ipsen | U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia ipsen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPN60340 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07623187 ↗ |
| Route | Intravenous | “IPN60340 per protocol by intravenous (IV) infusion in each 28-day treatment cycle” NCT07623187 ↗ |